Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Highly Efficient Generation of Transgenically Augmented Car Nk Cells Overexpressing Cxcr4 Publisher Pubmed



Jamali A1, 2, 3 ; Hadjati J4 ; Madjd Z1, 5 ; Mirzaei HR4 ; Thalheimer FB2 ; Agarwal S2 ; Bonig H6, 7, 8 ; Ullrich E3, 9, 10 ; Hartmann J11
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Advanced Technologies in Medicine, Department of Molecular Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany
  3. 3. Experimental Immunology, Division of Stem Cell Transplantation and Immunology, Childrens Hospital, Goethe University, Frankfurt, Germany
  4. 4. Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran
  6. 6. Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt, Germany
  7. 7. German Red Cross Blood Service Baden-Wurttemberg-Hessen, Frankfurt, Germany
  8. 8. Department of Medicine, Division of Hematology, University of Washington School of Medicine, Seattle, WA, United States
  9. 9. German Cancer Consortium, German Cancer Research Center, DKFZ, Heidelberg, Germany
  10. 10. Frankfurt Cancer Institute, Frankfurt, Germany
  11. 11. Division of Molecular Biotechnology, Paul-Ehrlich-Institut, Langen, Germany

Source: Frontiers in Immunology Published:2020


Abstract

Natural killer (NK) cells are a noteworthy lymphocyte subset in cancer adoptive cell therapy. NK cells initiate innate immune responses against infections and malignancies with natural cytotoxicity, which is independent of foreign antigen recognition. Based on these substantive features, genetically modifying NK cells is among the prime goals in immunotherapy but is currently difficult to achieve. Recently, we reported a fully human CAR19 construct (huCAR19) with remarkable function in gene-modified T-cells. Here, we show efficient and stable gene delivery of huCAR19 to primary human NK cells using lentiviral vectors with transduction efficiencies comparable to those achieved with NK cell lines. These huCAR19 NK cells display specific and potent cytotoxic activity against target cells. To improve homing of NK cells to the bone marrow, we augmented huCAR19 NK cells with the human CXCR4 gene, resulting in transgenically augmented CAR NK cells (TRACKs). Compared to conventional CAR NK cells, TRACKs exhibit enhanced migration capacity in response to recombinant SDF-1 or bone marrow stromal cells while retaining functional and cytolytic activity against target cells. Based on these promising findings, TRACKs may become a novel candidate for immunotherapeutic strategies in clinical applications. © Copyright © 2020 Jamali, Hadjati, Madjd, Mirzaei, Thalheimer, Agarwal, Bonig, Ullrich and Hartmann.
Other Related Docs
15. Car-Nk Cells: A Promising Cellular Immunotherapy in Lymphoma, Expert Opinion on Biological Therapy (2023)
19. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)